Published in Nat Clin Pract Rheumatol on May 01, 2007
Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol (2011) 1.34
Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol (2009) 1.30
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med (2008) 1.26
Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience (2008) 1.16
Advances in the understanding of the mechanism of action of IVIg. J Neurol (2008) 1.15
Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med (2009) 1.15
The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes. J Immunol (2012) 1.04
Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00
Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol (2010) 1.00
DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci U S A (2009) 0.94
Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion. Case Rep Med (2010) 0.85
Autoimmunity: CTLA-4: a key protein in autoimmunity. Nat Rev Rheumatol (2009) 0.80
Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukoc Biol (2013) 0.79
Immune mediated diseases and immune modulation in the neurocritical care unit. Neurotherapeutics (2012) 0.78
sHLA-I Contamination, a novel mechanism to explain ex vivo/in vitro modulation of IL-10 synthesis and release in CD8(+) T lymphocytes and in neutrophils following intravenous immunoglobulin infusion. J Clin Immunol (2010) 0.76
Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin. Nat Rev Drug Discov (2009) 0.76
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. Biologics (2009) 0.76
Attenuation of Postischemic Genomic Alteration by Mesenchymal Stem Cells: a Microarray Study. Mol Cells (2016) 0.75
Nanomedicine delivers promising treatments for rheumatoid arthritis. Nanomedicine (Lond) (2015) 0.75
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature (2009) 3.07
Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol (2012) 2.70
Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol (2004) 2.56
Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol (2007) 2.14
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood (2007) 1.83
High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med (2003) 1.80
Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy (2007) 1.75
A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation. Cardiovasc Res (2012) 1.63
The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med (2002) 1.62
Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol (2007) 1.57
The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther (2004) 1.56
Transition towards antigen-binding promiscuity of a monospecific antibody. Mol Immunol (2006) 1.54
Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood (2010) 1.53
Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood (2013) 1.48
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood (2002) 1.46
Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12-26 study. AIDS (2003) 1.45
High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis (2004) 1.39
Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol (2008) 1.35
Shortage of human intravenous immunoglobulin--reasons and possible solutions. Nat Clin Pract Neurol (2007) 1.35
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A (2008) 1.34
Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood (2004) 1.30
Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol (2009) 1.30
Metrics: journal's impact factor skewed by a single paper. Nature (2010) 1.29
Compartmentalization of HIV-1 between breast milk and blood of HIV-infected mothers. Virology (2002) 1.25
PE_PGRS antigens of Mycobacterium tuberculosis induce maturation and activation of human dendritic cells. J Immunol (2010) 1.25
Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol (2011) 1.24
Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A (2004) 1.24
Src homology 3-interacting domain of Rv1917c of Mycobacterium tuberculosis induces selective maturation of human dendritic cells by regulating PI3K-MAPK-NF-kappaB signaling and drives Th2 immune responses. J Biol Chem (2010) 1.20
Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol (2011) 1.20
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood (2006) 1.20
Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci (2009) 1.16
Reduced immunoregulatory CD31+ T cells in patients with atherosclerotic abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol (2005) 1.15
Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS (2002) 1.14
Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol (2007) 1.14
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci (2004) 1.13
Dual role of CpG-stimulated B cells in the regulation of dendritic cells: comment on the article by Berggren et al. Arthritis Rheum (2013) 1.10
Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today (2007) 1.09
Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood (2003) 1.09
Human basophils lack the capacity to drive memory CD4⁺ T cells toward the IL-22 response. J Allergy Clin Immunol (2013) 1.09
Intravenous immunoglobulin-mediated regulation of Notch ligands on human dendritic cells. J Allergy Clin Immunol (2013) 1.07
Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T-cells. J Am Coll Cardiol (2007) 1.06
Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol (2002) 1.06
Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia (2002) 1.06
Interferon-α inhibition by intravenous immunoglobulin is independent of modulation of the plasmacytoid dendritic cell population in the circulation: comment on the article by Wiedeman et al. Arthritis Rheumatol (2014) 1.05
Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr (2005) 1.04
Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS (2009) 1.03
Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci (2007) 1.01
Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women. J Infect Dis (2003) 1.00
Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol (2010) 1.00
The antiinflammatory IgG. N Engl J Med (2008) 1.00
High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci U S A (2005) 0.99
Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. J Rheumatol (2012) 0.98
Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J Biol Chem (2005) 0.98
Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol (2005) 0.98
Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer (2008) 0.97
Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev (2008) 0.96
Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J Immunol (2007) 0.95
DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci U S A (2009) 0.94
Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: insights from modeling. Int J Drug Policy (2014) 0.94
Contraceptive use in HIV-positive women. J Acquir Immune Defic Syndr (2004) 0.93
Common variable immunodeficiency: the immune system in chaos. Trends Mol Med (2005) 0.93
The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood (2013) 0.93
High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr (2005) 0.92
Circulating human basophils lack the features of professional antigen presenting cells. Sci Rep (2013) 0.92
A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2007) 0.92
The proatherogenic role of T cells requires cell division and is dependent on the stage of the disease. Arterioscler Thromb Vasc Biol (2005) 0.91
Sonic hedgehog-dependent induction of microRNA 31 and microRNA 150 regulates Mycobacterium bovis BCG-driven toll-like receptor 2 signaling. Mol Cell Biol (2012) 0.90